MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Vlad Vitoc Acquires 73,000 Shares of Stock

Key Points

• CEO Vlad Vitoc purchased 73,000 MAIA shares at an average price of $1.37, investing $100,010 and increasing his ownership by 7.48% to 1,049,121 shares.
• MAIA shares rose 6.9% and opened at $1.39, with the stock trading between $0.87 and $3.19 over the past 12 months and carrying an $84.55 million market capitalization.
• The clinical-stage biopharmaceutical company reported a quarterly loss of $0.13 per share, missing estimates by $0.02; institutional investors own 5.65% of its stock.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) CEO Vlad Vitoc purchased 73,000 shares of the firm's stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average price of $1.37 per share, for a total transaction of $100,010.00. Following the acquisition, the chief executive officer owned 1,049,121 shares of the company's stock, valued at $1,437,295.77. The trade was a 7.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

MAIA Biotechnology Stock Up 6.9%

Shares of MAIA stock opened at $1.39 on Tuesday. The firm has a market cap of $84.55 million, a price-to-earnings ratio of -2.24 and a beta of 0.25. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19. The stock has a 50-day moving average price of $1.35 and a 200 day moving average price of $1.39.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). Sell-side analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of MAIA. Centric Wealth Management acquired a new position in shares of MAIA Biotechnology in the 2nd quarter valued at $1,107,000. Cable Car Capital LP acquired a new stake in shares of MAIA Biotechnology during the second quarter worth $741,000. BlackRock Inc. bought a new stake in MAIA Biotechnology in the second quarter valued at about $580,000. Corsair Capital Management L.P. bought a new stake in MAIA Biotechnology in the first quarter valued at about $140,000. Finally, Susquehanna International Group LLP acquired a new position in MAIA Biotechnology in the second quarter valued at about $51,000. 5.65% of the stock is owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.